TMCI

New Innovations at ACFAS Conference: Treace Medical Concepts will showcase advanced technologies and clinical evidence for its Lapiplasty® and Adductoplasty® procedures at the 2025 ACFAS Annual Scientific Conference, highlighting their commitment to improving surgical outcomes for bunion patients.

Minimally Invasive Surgical Solutions: The company introduces several new systems, including Nanoplasty™ and Percuplasty™, designed for minimally invasive osteotomies, along with the SpeedMTP™ implant for bunion-related joint fusions, enhancing surgical options for foot deformities.

Insider Trading Activity: Sean F. Scanlan, Chief Innovation Officer of $TMCI, sold 50,000 shares for approximately $398,460, reducing his holdings to 364,081 shares. In the past six months, there have been two insider trades involving $TMCI stock, one purchase and one sale.

Analyst Ratings and Institutional Activity: Recent reports show that 61 institutional investors increased their positions in $TMCI, while 85 decreased theirs. Analysts have issued two buy ratings and set a median price target of $14.5 for the stock over the last six months.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Analyst Ratings: Richard Newitter from Truist Financial maintains a Hold rating on Treace Medical Concepts (TMCI) with a price target of $9.50, while Morgan Stanley also issued a Hold rating and Lake Street upgraded to Buy.

Company Performance: Treace Medical reported a quarterly revenue of $68.71 million and a GAAP net loss of $501 thousand, showing improvement compared to the previous year's revenue and loss, alongside positive insider sentiment as CEO John T. Treace purchased shares worth $524K.

CEO Stock Purchase: Treace Medical's CEO, John Treace, purchased 60,000 shares of the company's stock for $524,000 on March 4th, leading to a 4% increase in share price after hours.

Market Insights: The article highlights Treace Medical's recent growth and innovation, including strong earnings reports and upgrades from analysts.

Insider Trading Activity: John T. Treace, CEO of $TMCI, purchased 60,000 shares for approximately $524,064, increasing his holdings by about 0.9%, with total ownership now at 6,796,190 shares. In the past six months, there have been two insider purchases and no sales reported.

Institutional Investor Movements: In the latest quarter, 61 institutional investors increased their positions in $TMCI stock while 85 reduced theirs, indicating mixed sentiment among institutional stakeholders.

Analyst Ratings on Healthcare Stocks: Analysts have expressed bullish sentiments on Verve Therapeutics, Treace Medical Concepts, and Jasper Therapeutics, with strong buy ratings and significant upside potential for each stock.

Price Targets and Performance: Verve Therapeutics has a price target of $31.00, Treace Medical Concepts at $11.50, and Jasper Therapeutics at $60.89, indicating substantial growth opportunities based on current share prices.

Pinterest's Financial Performance: Pinterest, Inc. shares surged 20.5% in pre-market trading after reporting fourth-quarter revenue of $1.15 billion, exceeding estimates, although earnings per share fell short of expectations.

Market Movements: Several stocks experienced significant pre-market trading changes, with FitLife Brands gaining 138.2% due to a stock split, while Nikola Corporation dropped 29.7% amid bankruptcy concerns.

Financial Results Announcement: Treace Medical Concepts, Inc. will release its financial results for Q4 and the full year of 2024 on February 27, 2025, followed by a conference call at 4:30 pm ET for discussion and questions.

Company Overview: Treace specializes in surgical treatments for bunions and midfoot deformities, offering innovative procedures like Lapiplasty® and Adductoplasty®, aimed at improving patient outcomes and expanding their market presence.

Analyst Upgrade: BTIG analyst Ryan Zimmerman upgraded Treace Medical Concepts (TMCI) to a Buy with a price target of $16.00, while the current analyst consensus is a Moderate Buy with an average price target of $11.50.

Company Performance: Treace Medical reported quarterly revenue of $45.09 million and a GAAP net loss of $15.36 million for the quarter ending September 30, showing improvement from the previous year's revenue and loss figures.

INNOVATE Corp Stock Surge: INNOVATE Corp's shares rose 19.4% to $6.10 in pre-market trading following FDA approval of MediBeacon’s TGFR System for kidney function testing.

Market Movements: Several stocks experienced significant changes, with EON Resources Inc gaining 89.2% and Canoo Inc plummeting 72.3% after announcing bankruptcy.

Versus Systems Inc. Expansion: Shares of Versus Systems Inc. surged 71.2% in pre-market trading after the company announced its expansion into the Brazilian market to enhance its international presence.

Market Movements: Several stocks saw significant pre-market movements, with iSpecimen Inc. gaining 49.1% and Beasley Broadcast Group Inc. dropping 43.8%, reflecting a mix of positive and negative trends among various companies.

Preliminary Revenue Announcement: Treace Medical Concepts, Inc. reported a nearly 10% increase in preliminary revenue for Q4 and a 12% increase for the full year 2024 compared to the previous year, estimating Q4 revenue between $68.4 million and $68.8 million, and full-year revenue between $209 million and $209.4 million.

Stock Performance: Following the announcement, Treace's stock rose by 12.64%, reaching $8.20 on the Nasdaq, surpassing analysts' average revenue predictions for both the fourth quarter and the full year.

Investigation Announcement: The Law Offices of Frank R. Cruz are investigating Treace Medical Concepts, Inc. for potential violations of federal securities laws following a significant drop in stock price after the company revised its financial guidance downward by $20 million.

Stock Price Impact: After Treace reported increased competition and lower financial expectations, its stock plummeted by 62.5%, closing at $4.17 per share, resulting in losses for investors.

Stock News Highlights: CompoSecure is spinning off Resolute Holdings, Sangamo regains rights to a hemophilia treatment from Pfizer, EHang raises Q4 revenue guidance, and the FTC has referred a case against Dave Inc. to the DOJ.

Wall Street Analyst Calls: Ralph Lauren and Yum! Brands received upgrades to Buy due to rising margins and growth prospects, while Canoo was downgraded to Hold; Vertex and Treace Medical received bullish initiations.

Analyst Ratings Updates: Lake Street analyst Ben Haynor initiated coverage on Treace Medical Concepts (TMCI) with a Buy rating and a price target of $14.5, while DA Davidson's William Jellison also gave Vertex, Inc. (VERX) a Buy rating with a price target of $62.

Current Stock Prices: Treace Medical Concepts shares closed at $6.88, and Vertex shares closed at $53.05 as of Monday.

Real-time Intelligence for Traders: Benzinga Pro offers the fastest news alerts and exclusive stories to help traders make informed decisions in the stock market.

Community of Serious Traders: Over 10,000 traders are part of the Benzinga Pro community, benefiting from accurate market intelligence and timely updates.

New Product Launch: Treace Medical Concepts has announced the limited market release of its Percuplasty™ Percutaneous 3D Bunion Correction System, aimed at improving surgical treatment for bunions with minimally invasive techniques.

Future Plans: Full commercialization of the Percuplasty™ System is expected in the second half of 2025, as the company aims to expand its share in the $5B US bunion market and enhance access to advanced surgical options for patients and surgeons.

Analyst Ratings Overview: Treace Medical Concepts has received mixed evaluations from analysts over the past three months, with a total of four ratings indicating indifference and no bullish or bearish sentiments. The average 12-month price target is $7.6, reflecting a slight increase from previous estimates.

Financial Performance Insights: The company shows positive revenue growth of approximately 10.62%, but struggles with profitability as indicated by a net margin of -34.07% and an ROE of -14.15%. Additionally, its debt-to-equity ratio of 0.67 suggests a relatively sound financial structure compared to industry norms.

Introduction of MicroQuad™ Implants: Treace Medical Concepts has successfully completed initial cases using its new SpeedPlate™ MicroQuad™ implants, which enhance the capabilities of their existing SpeedPlate™ platform for minimally invasive bunion surgeries.

Future Market Expansion: The company plans to expand access to the MicroQuad™ implant in the first half of 2025, responding to increasing demand from surgeons and patients for effective and minimally invasive surgical options.